Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
GSK announced updated results from a phase II study evaluating Jemperli (dostarlimab-gxly) for treating mismatch repair deficient (dMMR) locally advanced rectal cancer. The trial, conducted with Memorial Sloan Kettering Cancer Center, showed a 100% clinical complete response (cCR) in 42 patients. The results, presented at the 2024 ASCO Annual Meeting, indicate no evidence of disease with a median follow-up of 26.3 months for the first 24 evaluated patients. The study highlights the potential of Jemperli as a non-surgical, first-line treatment option, addressing the negative impacts of current standard treatments. GSK is also advancing further studies, including AZUR-1 and AZUR-2 clinical trials, to evaluate Jemperli in various colorectal cancers.
- 100% clinical complete response (cCR) in 42 patients.
- No evidence of disease with a median follow-up of 26.3 months in the first 24 patients.
- No grade 3 or higher adverse events reported.
- Potential to replace chemotherapy, radiation, and surgery as a first-line treatment.
- Ongoing registrational studies (AZUR-1 and AZUR-2) to further evaluate efficacy.
- Jemperli is not yet approved for frontline treatment of locally advanced dMMR rectal cancer.
- Current standard of care (SoC) has significant long-term adverse effects.
- One-third of patients with current SoC die from distant metastasis.
The updated clinical data for Jemperli (dostarlimab-gxly) in treating mismatch repair deficient (dMMR) locally advanced rectal cancer is quite extraordinary. Achieving a 100% clinical complete response (cCR) rate in 42 patients is an outcome that challenges the current standard of care. Typically, the treatment for dMMR rectal cancer involves a combination of chemotherapy, radiation and surgery, which often results in significant quality-of-life issues, such as bowel, urinary and sexual dysfunction. The data indicates that Jemperli offers a potential non-surgical pathway, preserving the patient's quality of life while effectively managing the cancer. This could fundamentally change the treatment paradigm for these patients, if further studies confirm these results.
Another important aspect is the reported safety and tolerability profile, which aligns with the known safety profile of the drug—no adverse events of grade 3 or higher were observed. This is particularly significant, as the current treatments can lead to severe long-term side effects. The long-term follow-up (median of 26.3 months) further supports the durability of the response, which is a critical factor for any new cancer treatment.
However, investors should be cautious as this is still a phase II trial. Larger phase III trials, like AZUR-1 and AZUR-2, will be key to confirming these promising results. The potential benefits include a significant reduction in the need for invasive surgeries and associated complications, but we must wait for more extensive data to validate these findings.
From an oncological perspective, the results of the phase II trial for Jemperli are groundbreaking. A complete pathological response in all 42 patients suggests that dostarlimab-gxly could be a game-changer for patients with dMMR rectal cancer. The current standard of care involves extensive and often debilitating treatments, with a significant portion of patients still facing mortality due to distant metastasis. The ability of Jemperli to achieve complete response without traditional therapies could revolutionize the approach to treatment for these patients.
The fact that the study was conducted at a reputable institution like Memorial Sloan Kettering Cancer Center adds to the credibility of the findings. The absence of grade 3 or higher adverse events is particularly noteworthy, given that traditional treatments can lead to severe complications. This matches well with the pursuit of less invasive, more tolerable cancer treatments. While these results are promising, it is important to note that dostarlimab-gxly is still not approved for this specific indication and its long-term efficacy and safety will need to be further validated in larger, more diverse patient populations.
Ultimately, the implications for patients are enormous, potentially offering a life without the severe side effects of chemotherapy and surgery. However, these are early results and larger trials will be necessary to confirm efficacy and safety before it can become a new standard of care.
From a financial standpoint, the results from the phase II trial of Jemperli (dostarlimab-gxly) could have substantial implications for GSK. The potential to disrupt the current standard of care for dMMR rectal cancer means that Jemperli could capture significant market share. The existing treatments involve costly and extensive procedures, such as surgery and chemoradiotherapy, which can be both expensive and debilitating for patients. A drug that offers a non-invasive, highly effective alternative could see rapid adoption, assuming it passes further regulatory hurdles.
The market for colorectal cancer therapies is substantial. With registrational studies like AZUR-1 and AZUR-2 underway, if successful, this drug could lead to a significant increase in revenue for GSK. However, it is important to be cautious—these are still early-phase results. The phase III trials will be instrumental in determining whether these initial findings can be replicated on a larger scale.
For stakeholders, the short-term impact could be positive, as these results may drive stock price appreciation based on investor optimism and potential future revenue streams. Long-term implications will depend on the outcomes of the larger trials and eventual regulatory approval. Overall, the financial outlook appears promising but remains contingent on further clinical success and market acceptance.
- Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
- New treatment options are needed for patients facing negative impacts to quality-of-life with current standard of care
- Additional registrational studies of dostarlimab-gxly in dMMR/microsatellite instability-high rectal (MSI-H) and colorectal cancer are recruiting
These late-breaking data are being presented today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (May 31 – June 4) in
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The data showing no evidence of disease in 42 patients is remarkable. These results bring us one step closer to understanding the potential of dostarlimab-gxly in this curative-intent setting for patients with dMMR locally advanced rectal cancer. We look forward to evaluating dostarlimab-gxly in certain colorectal cancers in our ongoing AZUR-1 and AZUR-2 registrational studies.”
The current standard of care (SoC) for patients with dMMR/microsatellite instability-high (MSI-H) locally advanced rectal cancer is initial treatment with chemotherapy plus radiation followed by surgery to remove the tumor along with portions of the intestine and/or surrounding tissue.1 This results in initial positive outcomes for most patients, but nearly one-third ultimately die from cancer that has spread to other parts of the body (distant metastasis).2 Additionally, the surgery and chemoradiotherapy associated with SoC can lead to long-term adverse effects that have a significantly negative impact on quality of life, including bowel, urinary and sexual dysfunction, secondary cancers and infertility.1
Andrea Cercek, MD, Section Head of Colorectal Cancer and Co-Director of the Center for Young Onset Colorectal and Gastrointestinal Cancer, MSK, and Principal Investigator of the phase II study said: “These findings demonstrate the potential of dostarlimab-gxly as a novel approach to treating locally advanced dMMR rectal cancer that leads to durable complete tumor regression without the need for life-altering treatment. As a clinician, I’ve seen firsthand the debilitating impact of standard treatment of dMMR rectal cancer and am thrilled about the potential of dostarlimab-gxly in these patients.”
The safety and tolerability profile of dostarlimab-gxly was generally consistent with the known safety profile of the agent. No adverse events of grade 3 or higher were reported in this trial.
Dostarlimab-gxly is not approved anywhere in the world for the frontline treatment of locally advanced dMMR rectal cancer. GSK is advancing studies evaluating dostarlimab-gxly in patients with advanced/metastatic stages of dMMR/MSI-H colorectal cancer through its AZUR clinical trial programme. AZUR-1 is a global, multi-center, open-label, phase II registrational clinical trial investigating the efficacy and safety of dostarlimab-gxly as monotherapy – as a replacement for chemotherapy, radiation and/or surgery – for treatment-naïve patients with dMMR/MSI-H locally advanced rectal cancer. The AZUR-1 trial aims to confirm the findings of the supported collaborative study in locally advanced dMMR rectal cancer led by Dr. Cercek at MSK. AZUR-2 is a phase III trial evaluating the efficacy of perioperative dostarlimab-gxly compared with SoC in participants with untreated T4N0 or Stage III (resectable) dMMR/MSI-H colon cancer.
About dMMR/MSI-H rectal cancer
Rectal cancer is a form of cancer that starts in the rectum, the final section of the large intestine, and is often categorized as part of a group of cancers called colorectal cancer.3 Colorectal cancer is the third most commonly diagnosed cancer in the world.4 In the US, it is estimated that approximately 46,220 individuals are diagnosed annually with rectal cancer.5 Approximately 5
About Jemperli
Jemperli is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.12
Jemperli was discovered by AnaptysBio, Inc. and licensed to TESARO, Inc., under a collaboration and exclusive license agreement signed in March 2014. Under this agreement, GSK is responsible for the ongoing research, development, commercialization, and manufacturing of Jemperli, and cobolimab (GSK4069889), a TIM-3 Antagonist.
Indications and Important Safety Information for JEMPERLI (dostarlimab-gxly)
- JEMPERLI, in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high (MSI-H).
-
JEMPERLI, as a single agent, is indicated for the treatment of adult patients with dMMR recurrent or advanced:
- EC, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation, or
- solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Important Safety Information
Severe and Fatal Immune-Mediated Adverse Reactions
- Immune-mediated adverse reactions, which can be severe or fatal, can occur in any organ system or tissue and can occur at any time during or after treatment with a PD-1/PD-L1–blocking antibody, including JEMPERLI.
- Monitor closely for signs and symptoms of immune-mediated adverse reactions. Evaluate liver enzymes, creatinine, and thyroid function tests at baseline and periodically during treatment. For suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.
- Based on the severity of the adverse reaction, withhold or permanently discontinue JEMPERLI. In general, if JEMPERLI requires interruption or discontinuation, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone or equivalent) until improvement to ≤Grade 1. Upon improvement to ≤Grade 1, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reaction is not controlled with corticosteroids.
Immune-Mediated Pneumonitis
-
JEMPERLI can cause immune-mediated pneumonitis, which can be fatal. In patients treated with other PD-1/PD-L1–blocking antibodies, the incidence of pneumonitis is higher in patients who have received prior thoracic radiation. Pneumonitis occurred in
2.3% (14/605) of patients, including Grade 2 (1.3% ), Grade 3 (0.8% ), and Grade 4 (0.2% ) pneumonitis.
Immune-Mediated Colitis
-
Colitis occurred in
1.3% (8/605) of patients, including Grade 2 (0.7% ) and Grade 3 (0.7% ) adverse reactions. Cytomegalovirus infection/reactivation have occurred in patients with corticosteroid-refractory immune-mediated colitis. In such cases, consider repeating infectious workup to exclude alternative etiologies.
Immune-Mediated Hepatitis
-
JEMPERLI can cause immune-mediated hepatitis, which can be fatal. Grade 3 hepatitis occurred in
0.5% (3/605) of patients.
Immune-Mediated Endocrinopathies
-
Adrenal Insufficiency
-
Adrenal insufficiency occurred in
1.2% (7/605) of patients, including Grade 2 (0.5% ) and Grade 3 (0.7% ). For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment per institutional guidelines, including hormone replacement as clinically indicated. Withhold or permanently discontinue JEMPERLI depending on severity.
-
Adrenal insufficiency occurred in
-
Hypophysitis
-
JEMPERLI can cause immune-mediated hypophysitis. Grade 3 hypophysitis occurred in
0.4% (1/241) of patients receiving JEMPERLI in combination with carboplatin and paclitaxel. Grade 2 hypophysitis occurred in0.2% (1/605) of patients receiving JEMPERLI as a single agent. Initiate hormone replacement as clinically indicated. Withhold or permanently discontinue JEMPERLI depending on severity.
-
JEMPERLI can cause immune-mediated hypophysitis. Grade 3 hypophysitis occurred in
-
Thyroid Disorders
-
Grade 2 thyroiditis occurred in
0.5% (3/605) of patients. Grade 2 hypothyroidism occurred in12% (28/241) of patients receiving JEMPERLI in combination with carboplatin and paclitaxel. Grade 2 hypothyroidism occurred in8% (46/605) of patients receiving JEMPERLI as a single agent. Hyperthyroidism occurred in3.3% (8/241) of patients receiving JEMPERLI in combination with carboplatin and paclitaxel, including Grade 2 (2.9% ) and Grade 3 (0.4% ). Hyperthyroidism occurred in2.3% (14/605) of patients receiving JEMPERLI as a single agent, including Grade 2 (2.1% ) and Grade 3 (0.2% ). Initiate thyroid hormone replacement or medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue JEMPERLI depending on severity.
-
Grade 2 thyroiditis occurred in
-
Type 1 Diabetes Mellitus, Which Can Present with Diabetic Ketoacidosis
-
JEMPERLI can cause type 1 diabetes mellitus, which can present with diabetic ketoacidosis. Grade 3 type 1 diabetes mellitus occurred in
0.4% (1/241) of patients receiving JEMPERLI in combination with carboplatin and paclitaxel. Grade 3 type 1 diabetes mellitus occurred in0.2% (1/605) of patients receiving JEMPERLI as a single agent. Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold or permanently discontinue JEMPERLI depending on severity.
-
JEMPERLI can cause type 1 diabetes mellitus, which can present with diabetic ketoacidosis. Grade 3 type 1 diabetes mellitus occurred in
Immune-Mediated Nephritis with Renal Dysfunction
-
JEMPERLI can cause immune-mediated nephritis, which can be fatal. Grade 2 nephritis, including tubulointerstitial nephritis, occurred in
0.5% (3/605) of patients.
Immune-Mediated Dermatologic Adverse Reactions
-
JEMPERLI can cause immune-mediated rash or dermatitis. Bullous and exfoliative dermatitis, including
Stevens -Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS), have occurred with PD-1/PD-L1–blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-bullous/exfoliative rashes. Withhold or permanently discontinue JEMPERLI depending on severity.
Other Immune-Mediated Adverse Reactions
-
The following clinically significant immune-mediated adverse reactions occurred in <
1% of the 605 patients treated with JEMPERLI or were reported with the use of other PD-1/PD-L1–blocking antibodies. Severe or fatal cases have been reported for some of these adverse reactions.- Nervous System: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis, Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy
- Cardiac/Vascular: Myocarditis, pericarditis, vasculitis
- Ocular: Uveitis, iritis, other ocular inflammatory toxicities. Some cases can be associated with retinal detachment. Various grades of visual impairment to include blindness can occur
- Gastrointestinal: Pancreatitis, including increases in serum amylase and lipase levels, gastritis, duodenitis
- Musculoskeletal and Connective Tissue: Myositis/polymyositis, rhabdomyolysis and associated sequelae including renal failure, arthritis, polymyalgia rheumatica
- Endocrine: Hypoparathyroidism
- Other (Hematologic/Immune): Autoimmune hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenia, solid organ transplant rejection, other transplant (including corneal graft) rejection
Infusion-Related Reactions
-
Severe or life-threatening infusion-related reactions have been reported with PD-1/PD-L1–blocking antibodies. Severe infusion-related reactions (Grade 3) occurred in
0.2% (1/605) of patients receiving JEMPERLI. Monitor patients for signs and symptoms of infusion-related reactions. Interrupt or slow the rate of infusion or permanently discontinue JEMPERLI based on severity of reaction.
Complications of Allogeneic HSCT
- Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after treatment with a PD-1/PD-L1–blocking antibody, which may occur despite intervening therapy. Monitor patients closely for transplant-related complications and intervene promptly.
Embryo-Fetal Toxicity and Lactation
- Based on its mechanism of action, JEMPERLI can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with JEMPERLI and for 4 months after their last dose. Because of the potential for serious adverse reactions from JEMPERLI in a breastfed child, advise women not to breastfeed during treatment with JEMPERLI and for 4 months after their last dose.
Common Adverse Reactions
The most common adverse reactions (≥
The most common adverse reactions (≥
The most common adverse reactions (≥
Please see the full US Prescribing Information for JEMPERLI.
GSK in oncology
Oncology is an emerging therapeutic area for GSK where we are committed to maximizing patient survival with a current focus on hematologic malignancies, gynecologic cancers, and other solid tumors through breakthroughs in immuno-oncology and tumor-cell targeting therapies.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at us.gsk.com.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q1 Results for 2024.
Registered in
No. 3888792
Registered Office:
980 Great West Road
Brentford,
TW8 9GS
Dr. Cercek has financial interests related to GSK.
References
1. Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer. N Engl J Med 2022; 386: 2363-76.
2. Smith JJ, et al. Rectal Cancer Consortium. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer. 2015 Oct 23;15:767. doi: 10.1186/s12885-015-1632-z. PMID: 26497495; PMCID: PMC4619249.
3. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660.
4. SEER Explorer. SEER Explorer Application. Accessed April 19, 2024. Available at https://seer.cancer.gov/statistics-network/explorer/.
5. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. Doi:10.3322/caac.21820.
6. Cercek A, et al. Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. Clin Cancer Res. 2020 Jul 1;26(13):3271-3279. doi: 1158/1078-0432.CCR-19-3728. Epub 2020 Mar 6. PMID: 32144135; PMCID: PMC7348681.
7. Le DT, et al. PD-1 blockade in tumors with mismatch repair deficiency. N Engl J Med. 2015;372(26):2509-2520.
8. Marabelle A, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair deficient cancer: results from the Phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1-10.
9. National Cancer Institute at the National Institutes of Health. Definition of mismatch repair deficiency. Accessed April 19, 2024. Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/mismatch-repair-deficiency.
10. Lorenzi M, et al. Epidemiology of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) in solid tumors: a structured literature review. J Oncol. 2020. doi.org/10.1155/2020/1807929.
11. Zhao P, et al. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019;12(1):54. doi: 10.1186/s13045-019-0738-1.
12. Laken H, Kehry M, Mcneeley P, et al. Identification and characterization of TSR-042, a novel anti-human PD-1 therapeutic antibody. European Journal of Cancer. 2016;69, S102. doi:10.1016/s0959-8049(16)32902-1.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240602370374/en/
GSK inquiries
Media:
Tim Foley +44 (0) 20 8047 5502 (
Dan Smith +44 (0) 20 8047 5502 (
Kathleen Quinn +1 202 603 5003 (
Lyndsay Meyer +1 202 302 4595 (
Investor Relations:
Nick Stone +44 (0) 7717 618834 (
James Dodwell +44 (0) 20 8047 2406 (
Mick Readey +44 (0) 7990 339653 (
Josh Williams +44 (0) 7385 415719 (
Camilla Campbell +44 (0) 7803 050238 (
Steph Mountifield +44 (0) 7796 707505 (
Jeff McLaughlin +1 215 751 7002 (
Frannie DeFranco +1 215 751 4855 (
Source: GSK plc
FAQ
What were the results of GSK's Jemperli trial for rectal cancer?
When were the latest Jemperli trial results presented?
What is the current standard of care for dMMR rectal cancer?
Is Jemperli approved for frontline treatment of rectal cancer?